aiqbench analysis
This research introduces GS-MoE, a novel architecture combining cross-modal generalist models with modality-specific experts to address the limitations of pure Mixture-of-Experts in detecting rare pathologies within multimodal medical imaging. By fusing domain-constrained features, the model successfully recovers zero-F1 detections for six low-prevalence conditions while reducing active inference parameters by approximately 53% compared to dense baselines. The work highlights a critical architectural trade-off between specialization and shared representation that is essential for advancing robust AI in high-stakes diagnostic scenarios.
Generalist-Specialist Mixture-of-Experts for Rare Pathology Detection in Multimodal Imaging
arXiv:2609.18688v1 Announce Type: cross Abstract: AI models for multimodal medical imaging must balance modality-specific specialization with cross-modal shared representations, a trade-off that pure Mixture-of-Experts (MoE) architectures currently fail to satisfy. Expert-based routing improves in-domain learning but may sacrifice cross-modal signals, which appear particularly important for rare (low-prevalence) pathologies in our experiments. To resolve this, we introduce Generalist-Specialist-MoE (GS-MoE), a two-branch (MoE) architecture that couples a cross-modal generalist model with distinct modality-specific specialists (experts) via domain-constrained feature fusion. On RadImageNet (1.35M images, 165 pathologies, three modalities), GS-MoE recovers detection of six low-prevalence pathologies on which every baseline scores F1 $=$ 0, with per-class gains up to +0.60 F1. It attains this while even slightly exceeding dense and specialist-only MoE aggregate baselines (MCC 0.770), while using ${\sim}53\%$ fewer active parameters at inference than the strongest investigated dense model.
Abstract:AI models for multimodal medical imaging must balance modality-specific specialization with cross-modal shared representations, a trade-off that pure Mixture-of-Experts (MoE) architectures currently fail to satisfy. Expert-based routing improves in-domain learning but may sacrifice cross-modal signals, which appear particularly important for rare (low-prevalence) pathologies in our experiments. To resolve this, we introduce Generalist-Specialist-MoE (GS-MoE), a two-branch (MoE) architecture that couples a cross-modal generalist model with distinct modality-specific specialists (experts) via domain-constrained feature fusion. On RadImageNet (1.35M images, 165 pathologies, three modalities), GS-MoE recovers detection of six low-prevalence pathologies on which every baseline scores F1 $=$ 0, with per-class gains up to +0.60 F1. It attains this while even slightly exceeding dense and specialist-only MoE aggregate baselines (MCC 0.770), while using ${\sim}53\%$ fewer active parameters at inference than the strongest investigated dense model.
Computer Vision and Pattern Recognition (cs.CV); Artificial Intelligence (cs.AI)
arXiv:2609.18688 [cs.CV]
(or arXiv:2609.18688v1 [cs.CV] for this version)
https://doi.org/10.48550/arXiv.2609.18688 Focus to learn more arXiv-issued DOI via DataCite (pending registration)
arXivLabs is a framework that allows collaborators to develop and share new arXiv features directly on our website.
Both individuals and organizations that work with arXivLabs have embraced and accepted our values of openness, community, excellence, and user data privacy. arXiv is committed to these values and only works with partners that adhere to them.
Have an idea for a project that will add value for arXiv's community? Learn more about arXivLabs.
Full text under the publisher's open licence · 231 words
Related coverage
Cross-modal triage network: a multimodal deep learning framework for severity-based triage and visual explainability in chest radiographs
arXiv · Sep 7, 2026

[AINews] not much happened today
Latent Space · Sep 18, 2026

NVIDIA GTC Taipei at COMPUTEX: Live Updates on What’s Next in AI
NVIDIA · May 21, 2026
LUCAID: Agentic Multimodal AI for Lung Cancer Precision Pathology
arXiv · Aug 27, 2026